An ounce of prevention on a budget: A nonprofit approach to developing vaccines against neglected diseases

Expert Review of Vaccines

Volumn 5, Issue 2, 2006, Pages 189-198

  Bottazzi, Maria Elena ^a   Miles, Aaron P ^a   Diemert, David ^b   Hotez, Peter J ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b Albert B Sabin Vaccine Institute   (United States)

Author keywords

Hookworm; Necator americanus; Neglected tropical diseases; Product development; Public private partnership; Recombinant vaccine

Indexed keywords

ALBENDAZOLE; ALUMINUM HYDROXIDE; AZITHROMYCIN; DENGUE VACCINE; HOOKWORM VACCINE; IVERMECTIN; LEISHMANIA VACCINE; LEPROSTATIC AGENT; MEBENDAZOLE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN PURIFICATION; BACTERIAL INFECTION; CLINICAL TRIAL; DENGUE; DEVELOPING COUNTRY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; FERMENTATION; FILARIASIS; HEALTH CARE COST; HOOKWORM INFECTION; HUMAN; IMMUNOASSAY; LEISHMANIASIS; MEDICAL RESEARCH; MOLECULAR CLONING; NON PROFIT ORGANIZATION; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; SCHISTOSOMIASIS; STANDARDIZATION; TRACHOMA; TROPICAL DISEASE; BUDGET; ECONOMICS; METHODOLOGY; SYNTHESIS; TROPICAL MEDICINE;

BUDGETS; HUMANS; ORGANIZATIONS, NONPROFIT; TROPICAL MEDICINE; VACCINES;

EID: 33745430657     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.2.189     Document Type: Review

References (29)

1. Alonso PL, Sacarial J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 364, 1411-1420 (2004). •• First study to demonstrate that development of an effective vaccine against malaria (or any parasitic disease) is feasible.
2. Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. The global HIV/AIDS vaccine enterprise: scientific strategic plan. PLoS Med. 2, e25 (2005).
3. Haile M, Kallenius G. Recent developments in tuberculosis vaccines. Curr. Opin. Infect. Dis. 18, 211-215 (2005).
4. Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet 365, 1487-1498 (2005).
5. Hotez PJ, Ottesen E, Fenwick A, Molyneux D. The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. In: Hot Topics in Infection and Immunity in Children II. Pollard AJ, Finn A (Eds). Kluwer Academic/Plenum Publishers, Advances in Experimental Medicine and Biology (2006) (In press).
6. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria, a comprehensive pro-poor health policy and strategy for the developing world. PLoS Med. 3, e102 (2006). • Highlights the neglected tropical diseases as a group of conditions equivalent to the disease burden caused by HIV/AIDS, tuberculosis and malaria, and points out the importance of neglected tropical disease control in the fight against HIV/AIDS and malaria.
7. World Health Organization. Annex Table 3. Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002. The World Health Report 2004 - Changing History. WHO, Geneva, Switzerland, 126 (2004).
8. Molyneux DH, Hotez PJ, Fenwick A. 'Rapid impact' interventions: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med. 2, e336 (2005). • Describes the very large impact that a very small cost (a fraction of the cost to treat any one of 'the big three') could have on bringing improved health to millions of polyparasitized and disenfranchised poor.
9. Hotez PJ. Vaccines as instruments of foreign policy. EMBO Rep. 2, 862-868 (2001).
10. Widdus R, White K. Combating diseases associated with poverty, financing strategies for product development and the potential role of public-private partnerships. Initiative on Public-Private Partnerships for Health, Global Forum for Health Research, 10 (2004).
11. Morel CM, Acharya T, Broun D et al. Health innovation: the neglected capacity of developing countries to address neglected diseases. Science 309, 401-404 (2005). • Highlights the major features of the innovative developing countries and their importance for product development in poor countries.
12. Morel C, Broun D, Dangi A et al. Health innovation in developing countries to address diseases of the poor. Innovation Strategy Today 1, 1-15 (2005).
13. Goud GN, Bottazzi ME, Zhan B et al. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine 23, 4754-4764 (2005). • Describes production and characterization of the first vaccine against human hookworm.
14. Spack E. Minding the drug development gap. Scientist 19(21), 36-37 (2005).
15. Croft SL. Public-private partnership: from there to here. Trans. Royal Soc. Trop. Med. 99S, S9-S14 (2005).
16. Kaslow DC. Transmission-blocking vaccines. Chem. Immunol. 80, 287-307 (2002).
17. Saul A, Lawrence G, Allworth A et al. A human Phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide® ISA 720 adjuvant. Vaccine 23, 3076-3083 (2005).
18. Miles AP, McClellan HA, Rausch, KM et al. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 23, 2528-2537 (2005). • Details antigen modification in formulated vaccines and shows a correlation between modification and loss of potency.
19. Miles AP, Saul A. Extraction and characterization of vaccine antigens from water-in-oil adjuvant formulations. In: Methods in Molecular Biology, vol. 308: Therapeutic Proteins: Methods and Protocols. Smales MC, James DC (Eds). Humana Press Inc., Totowa, NJ, USA, 293-300 (2005).
20. Hotez PJ, Bethony J, Bottazzi ME, Brooker S Buss P. Hookworm: 'The Great Infection of Mankind'. PLoS Med. 2, e67 (2005).
21. International AIDS Vaccine Initiative www.iavi.org (Accessed February 21, 2006)
22. Pediatric Dengue Vaccine Initiative www.pdvi.org (Accessed January 9, 2006)
23. The Rockefeller Foundation www.rockfound.org (Accessed January 9, 2006)
24. The Bill and Melinda Gates Foundation www.gatesfoundation.org (Accessed January 9, 2006)
25. The Leishmaniasis Vaccine Initiative http://www.idri.org (Accessed January 9, 2006)
26. The World Health Organization Initiative for Vaccine Research, www.who.int/vaccine_research (Accesses February 22, 2006)
27. United Nations Children's Fund/United Nations Development Programme/World Bank/World Health Organization Special Program for Research and Training in Tropical Diseases www.who.int/tdr/ (Accessed February 21, 2006)
28. University of Nebraska-Lincoln (UNL) Bioprocess Development Facility, http://bpdf.unl.edu (Accessed January 9, 2006)
29. The Bioprocess Research Laboratory at Cornell University, http://foodmicro.foodsci.cornell.edu/Ludwig/facilities.htm (Accessed January 9, 2006)